We thus speculate that the underlying mechanisms of albuminuria reduction of SGLT2 inhibitors may differ according to the presence or absence of renal dysfunction, and that the amelioration of tubulo-interstitial disorders might be an important aspect of the anti-albuminuric effect of SGLT2 inhibitors in patients with renal dysfunction. Here, SLC5A2 is linked to Abnormal renal physiology.